Gallium MAL is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma

Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305-5655, USA.
Anticancer research (Impact Factor: 1.83). 11/2005; 26(3A):1739-43.
Source: PubMed


Hepatocellular carcinoma (HCC) is a particularly lethal cancer with few treatment options. Since gallium is known to accumulate specifically in HCC tumors but not in non-tumor liver, we investigated two gallium compounds, gallium nitrate (GaN) and gallium maltolate (GaM), as potential new agents for treating HCC.
The anti-proliferative and apoptotic activities of GaN and GaM were assessed in vitro using four HCC cell lines. HCC gene expression data was analyzed to provide a mechanistic rationale for using gallium in the treatment of HCC.
Both compounds showed dose-dependent antiproliferative activity in all four HCC cell lines after 6-day drug exposure (IC50 values range from 60-250 microM for gallium nitrate and 25-35 microM for gallium maltolate). Gallium maltolate at 30 microM additionally induced apoptosis after 6 days. HCC gene expression data showed significantly elevated expression of the M2 subunit of ribonucleotide reductase, which is a target for the antiproliferative activity of gallium.
These data support clinical testing of gallium maltolate, an orally active compound, in the treatment of HCC.

Download full-text


Available from: Lawrence R Bernstein
  • Source
    • "RRM2 is located in a region of frequent cytogenetic aberration in HCC [33]. Chua et al. suggested that gallium maltolate might be a promising chemotherapeutic agent for treatment of HCC by targeting RRM2 [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. Despite several efforts to elucidate molecular mechanisms involved in this cancer, they are still not fully understood. To acquire further insights into the molecular mechanisms of HCC, and to identify biomarkers for early diagnosis of HCC, we downloaded the gene expression profile on HCC with non-cancerous liver controls from the Gene Expression Omnibus (GEO) and analyzed these data using a combined bioinformatics approach. The dysregulated pathways and protein-protein interaction (PPI) network, including hub nodes that distinguished HCCs from non-cancerous liver controls, were identified. In total, 29 phenotype-related differentially expressed genes were included in the PPI network. Hierarchical clustering showed that the gene expression profile of these 29 genes was able to differentiate HCC samples from non-cancerous liver samples. Among these genes, CDC2 (Cell division control protein 2 homolog), MMP2 (matrix metalloproteinase-2) and DCN (Decorin were the hub nodes in the PPI network. This study provides a portfolio of targets useful for future investigation. However, experimental studies should be conducted to verify our findings.
    Full-text · Article · Oct 2013
  • Source
    • "In vitro and animal studies: Anticancer, including against hepatocellular carcinoma; effective in animal models of rheumatoid arthritis; antimicrobial: effective against P. aeruginosa, Rhodococcus equi, S. aureus, Staphylococcus epidermidis and other bacteria; antibiofilm Bernstein et al. (2000); Bernstein (2005); Chua et al. (2006) Human clinical studies: Oral formulation safe in Phase I trials; anecdotal efficacy observed in hepatocellular carcinoma, metastatic colon cancer, lymphoma. Topical formulation has shown anecdotal efficacy in pain, including postherpetic neuralgia, inflammation, actinic keratosis, and psoriasis Ga 8-quinolinolate (tris(8-quinolonato)Ga (III)) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gallium is not known to have any essential biological function, but it exerts a variety of therapeutically useful biological activities. Many of these activities derive from gallium’s ability to act as an irreducible mimic of ferric iron (Fe3+). Gallium’s ability to compete with other essential metals, particularly zinc, is likely responsible for some of its other biological activities.
    Full-text · Article · Jan 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The thesis project is devoted to the ‘search of antineoplastic ruthenium/platinum/copper complexes containing also intercalator ligands; such intercalators may show efficient DNA-cleaving and DNA-binding properties’. The studies have been carried out using a variety of techniques. Study of the in vitro cytotoxicity against human tumour cell lines along with cellular uptake has been the pivotal point of this research. Synthetic methodologies of the new complexes have been designed to establish structure-activity relation in several series of related complexes. Platinum complexes of derivatized-phenanthroline, pyridine and pyrimidine, have been synthesized and studied in detail for their biological activity. These complexes are different in structure and in overall charges, and were studied to elucidate the effects on the activity profile. A self-activating copper-complex formed from a unique amino-phenol ligand (Hpyramol) inspired the synthesis of platinum and ruthenium analogues. Biological studies including cellular uptake, conformational changes (CD and UV) and DNA cleavage have been performed to interpret the changes in activity profile upon various metal additions. Ruthenium complexes are known as suitable candidates for anticancer (specially as antimetastatic drugs) agents. A group of ruthenium(III) complexes has been studied for their anticancer activity and their DNA-binding properties. The extensive area of homo- or heterometallic dinuclear compounds opens up an interesting challenge towards the synthesis of complexes. The studies of different combinations viz., Ru-Ru, Cu-Cu and Pt-Pt, have been performed to design new series of anticancer complexes.
    Preview · Article ·
Show more